A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2019
Price : $35 *
At a glance
- Drugs Marstacimab (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Pfizer
- 06 Oct 2019 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 27 Aug 2019 Planned End Date changed from 1 Oct 2020 to 11 Aug 2020.
- 27 Aug 2019 Planned primary completion date changed from 1 Oct 2020 to 11 Aug 2020.